Prof. Remco A. Spanjaard

Boston University School of Medicine, USA

Email: remspan@gmail.com

Qualifications

1989 Ph.D., University of Leiden, Gene regulation

1984 M.Sc., University of Leiden, Cell Biology

1982 B.Sc., University of Leiden, Biology/Chemistry

Publications (selected)

1. Demary K, Wong L, Liou JS, Faller DV, Spanjaard RA. Redox-control of retinoic acid (RA) receptor activity: a novel mechanism for RA-resistance in melanoma cells. Endocrinology 2001; 142:2600-2605.
2. Krishna S, Brown N, Faller DV, Spanjaard RA. Differential effects of short chain fatty acids on head and neck squamous carcinoma cells. Laryngoscope 2002; 112:645-650.
3. Hoa M, Davis SL, Ames SJ, Spanjaard RA. Amplification of wild-type K-RAS promotes growth of head and neck squamous cell carcinoma. Cancer Res 2002; 62:7154-7156.
4. Chen JS, Faller DV, Spanjaard RA. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics? Curr Cancer Drug Targets 2003; 3:219-236.
5. Zhao X, Patton JR, Davis SL, Florence B, Ames SJ, Spanjaard RA. Regulation of nuclear receptor activity by a pseudouridine synthase through posttranscriptional modification of Steroid Receptor RNA Activator. Mol Cell 2004; 15:549-558.
6. Zhao X, Ayer RE, Davis SL, Ames SJ, Florence B, Torchinsky C, Liou JS, Shen L, Spanjaard RA. Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. Cancer Res 2005; 65:2125-2129.
7. Mork C, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 2005; 11:1091-1104.
8. Gu J, Zhao X, Spanjaard RA, Chen TC, Flannagan JN, Boosalis M, Perrine SP, Faller DV. Histone deacetylase-inhibitors sensitize human prostate cancer cell lines to growth suppression and apoptosis by retinoids. J Cancer Molecules 2006; 2:25-36.
9. Abujamra AL, Spanjaard RA, Akinsheye I, Zhao X, Faller DV, Ghosh SK. Leukemia virus long terminal repeat activates NFkappaB pathway by a TLR3-dependent mechanism. Virology 2006; 345:390-403.
10. Zhao X, Patton JR, Ghosh SK, Fischel-Ghodsian N, Shen L, Spanjaard RA.Pus3p and Pus1p-dependent pseudouridylation of steroid receptor RNA activator controls a functional switch that regulates nuclear receptor signaling. Mol Endocrinol 2007;21:686-699.
11. Spanjaard RA, Whren KM, Graves C, Bhawan J. Tumor necrosis factor receptor superfamily member TROY is a novel melanoma biomarker and potential therapeutic target. Int J Cancer 2007;120:1304-1310
12. Mork CN, Faller DV, Spanjaard RA. Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide. FEBS Lett 2007;581:5440-5444.
13. Rankin AM, Faller DV, Spanjaard RA. Telomerase inhibitors and ‘T-oligo’ as cancertherapeutics:contrasting molecular mechanisms of cytotoxicity. AntiCancer Drugs 2008; 19:329-338.
14. Zhao X, Graves C, Ames SJ, Spanjaard RA. Mechanism of regulation and suppression of melanoma invasiveness by novel retinoic acid receptor-γ target gene CHST10. Cancer Res 2009;69:5218-5225.
15. Flanagan JN, Zheng S, Chiang KC, Kittaka A, Sakaki T, Nakabayashi S, Zhao X, Spanjaard RA, Persons KS, Mathieu JS, Holick MF, Chen TC. Evaluation of 19-nor-2alpha-(3-hydroxypropyl)-1alpha,25-dihydroxyvitamin D3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 2009;29:3547-3553.